Ricardo P Garay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/579061/publications.pdf

Version: 2024-02-01

102	3,116	249298	190340
papers	citations	26 h-index	53 g-index

109	109	109	3041
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu. Expert Opinion on Investigational Drugs, 2021, 30, 749-758.	1.9	13
2	Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. Expert Opinion on Pharmacotherapy, 2021, 22, 2507-2519.	0.9	1
3	Pharmacotherapeutic approaches to treating depression during the perimenopause. Expert Opinion on Pharmacotherapy, 2019, 20, 1837-1845.	0.9	12
4	The development of glutamate-based antidepressants is taking longer than expected. Drug Discovery Today, 2018, 23, 1689-1692.	3.2	12
5	Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Review of Neurotherapeutics, 2017, 17, 593-609.	1.4	65
6	Vaccinating against depression or anxiety: is it plausible?. Expert Opinion on Biological Therapy, 2017, 17, 525-528.	1.4	4
7	AVP-786 for the treatment of agitation in dementia of the Alzheimerâ€™s type. Expert Opinion on Investigational Drugs, 2017, 26, 121-132.	1.9	40
8	Investigational drugs for treating agitation in persons with dementia. Expert Opinion on Investigational Drugs, 2016, 25, 973-983.	1.9	25
9	Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T		
10	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion on Pharmacotherapy, 2016, 17, 921-936.	0.9	26
11	Potential serotonergic agents for the treatment of schizophrenia. Expert Opinion on Investigational Drugs, 2016, 25, 159-170.	1.9	33
12	Investigational drugs for anxiety in patients with schizophrenia. Expert Opinion on Investigational Drugs, 2015, 24, 507-517.	1.9	21
13	Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment. Drug Discovery Today, 2014, 19, 1792-1800.	3.2	12
14	Novel drug discovery strategies for gout. Expert Opinion on Drug Discovery, 2013, 8, 183-189.	2.5	5
15	Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opinion on Drug Delivery, 2012, 9, 1319-1323.	2.4	465
16	Perspectives des uricases dans la goutte. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 17-22.	0.0	4
17	Therapeutic perspectives on uricases for gout. Joint Bone Spine, 2012, 79, 237-242.	0.8	48
18	Protein kinase A signalling is involved in the relaxant responses to the selective Î²-oestrogen receptor agonist diarylpropionitrile in rat aortic smooth muscle in vitro. Journal of Pharmacy and Pharmacology, 2011, 63, 222-229.	1.2	15

#	Article	IF	Citations
19	Impact of an educational program on the management of bipolar disorder in primary care. Bipolar Disorders, 2011, 13, 318-322.	1.1	5
20	Screening for bipolar disorder in patients consulting general practitioners in France. Journal of Affective Disorders, 2011, 130, 492-495.	2.0	19
21	Cyamemazine metabolites: effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs. Journal of Pharmacy and Pharmacology, 2010, 60, 1507-1513.	1.2	4
22	Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism. Neuropsychiatric Disease and Treatment, 2010, 6, 37.	1.0	13
23	Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes. European Journal of Pharmacology, 2008, 578, 142-147.	1.7	7
24	What can we learn from erythrocyte Naâ€“Kâ€“Cl cotransporter NKCC1 in human hypertension?. Pathophysiology, 2007, 14, 167-170.	1.0	12
25	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. European Journal of Pharmaceutical Sciences, 2007, 32, 357-366.	1.9	12
26	Therapeutic Efficacy and Mechanism of Action of Ethamsylate, a Long-Standing Hemostatic Agent. American Journal of Therapeutics, 2006, 13, 236-247.	0.5	32
27	Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. European Journal of Pharmacology, 2006, 532, 270-278.	1.7	16
28	Cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel and Naâ€“Kâ€“Cl cotransporter NKCC1 isoform mediate the vasorelaxant action of genistein in isolated rat aorta. European Journal of Pharmacology, 2006, 544, 126-131.	1.7	8
29	Role of chloride transport proteins in the vasorelaxant action of nitroprusside in isolated rat aorta. European Journal of Pharmacology, 2006, 553, 205-208.	1.7	4
30	Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats. European Journal of Pharmacology, 2005, 510, 149-156.	1.7	22
31	Calcium Dobesilate in the Treatment of Diabetic Retinopathy. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 221-232.	1.8	37
32	The hemostatic agent ethamsylate promotes platelet/leukocyte aggregate formation in a model of vascular injury. Fundamental and Clinical Pharmacology, 2004, 18, 423-430.	1.0	13
33	Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. European Journal of Pharmacology, 2004, 495, 217-224.	1.7	55
34	Isoosmotic shrinkage by self-stimulated outward Na-K-Cl cotransport in quail erythrocytes. Pflugers Archiv European Journal of Physiology, 2003, 447, 64-70.	1.3	3
35	Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochemical Pharmacology, 2003, 65, 435-440.	2.0	181
36	Vascular permeabilization by intravenous arachidonate in the rat peritoneal cavity: antagonism by antioxidants. European Journal of Pharmacology, 2003, 466, 199-205.	1.7	5

#	Article	IF	Citations
37	Vascular permeabilization by intravenous arachidonate in the rat peritoneal cavity: antagonism by ethamsylate. European Journal of Pharmacology, 2003, 466, 207-212.	1.7	6
38	Verapamil Reverts Acute Renal Functional Impairment Induced by Angiotensin II Converting Enzyme Inhibitors. Renal Failure, 2003, 25, 727-737.	0.8	4
39	Renal Naâ€“Kâ€“Cl cotransporter NKCC2 in Dahl salt-sensitive rats. Journal of Hypertension, 2002, 20, 721-727.	0.3	45
40	Soy Milk Lowers Blood Pressure in Men and Women with Mild to Moderate Essential Hypertension. Journal of Nutrition, 2002, 132, 1900-1902.	1.3	164
41	The hemostatic agent ethamsylate enhances P-selectin membrane expression in human platelets and cultured endothelial cells. Thrombosis Research, 2002, 107, 329-335.	0.8	15
42	Vasomotor Rhinitis: Clinical Efficacy of Azelastine Nasal Spray in Comparison with Placebo. Orl, 2001, 63, 76-81.	0.6	24
43	Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. European Journal of Pharmacology, 2001, 428, 277-286.	1.7	55
44	Natriuretic Effect of Equol. Journal of Medicinal Food, 1999, 2, 257-260.	0.8	2
45	Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha_{1A}â€adrenoceptor subtype in the rat. Fundamental and Clinical Pharmacology, 1999, 13, 50-58.	1.0	11
46	Antioxidant-angioprotective actions of calcium dobesilate in diabetic rats. International Journal of Angiology, 1999, 8, S2-S4.	0.2	8
47	Antioxidant-angioprotective actions of calcium dobesilate in diabetic rats. International Journal of Angiology, 1999, 8, S2-S4.	0.2	1
48	Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. European Journal of Pharmacology, 1998, 358, 213-220.	1.7	59
49	Salidiuretic Action by Genistein in the Isolated, Perfused Rat Kidney. Hypertension, 1998, 31, 706-711.	1.3	19
50	The erythrocyte Na,K,Cl cotransporter and its circulating inhibitor in Dahl salt-sensitive rats. Journal of Hypertension, 1998, 16, 1499-1504.	0.3	9
51	Renal and vascular actions of equol in the rat. Journal of Hypertension, 1997, 15, 1303-1308.	0.3	18
52	Purification and Chemical Characterization of a Potent Inhibitor of the Na-K-Cl Cotransport System in Rat Urine. Biochemical and Biophysical Research Communications, 1996, 221, 279-285.	1.0	17
53	Endogenous sodium-potassium-chloride cotransport inhibitor in congestive heart failure. Journal of the American College of Cardiology, 1996, 28, 1464-1470.	1.2	6
54	Reduction by (-)-Cicletanine of the Vascular Reactivity to Angiotensin II in Rats. Journal of Cardiovascular Pharmacology, 1996, 28, 564-570.	0.8	9

#	Article	IF	Citations
55	Evidence for (+)-cicletanine sulfate as an active natriuretic metabolite of cicletanine in the rat. European Journal of Pharmacology, 1995, 274, 175-180.	1.7	24
56	Inhibition of Na-K-Cl cotransport fluxes and salidiuretic action by an urinary extract of salt-loaded rats. Pflugers Archiv European Journal of Physiology, 1994, 426, 357-359.	1.3	11
57	Molybdenum uptake through the anion exchanger in human erythrocytes. Pflugers Archiv European Journal of Physiology, 1993, 424, 245-249.	1.3	12
58	A potent inhibitor of the Na+,K+,Cl??? cotransport system in urine from salt-loaded rats. Journal of Hypertension, 1993, 11, S266???S267.	0.3	3
59	A circulating inhibitor of the RBC membrane calcium pump in chronic renal failure. Kidney International, 1992, 42, 1328-1335.	2.6	29
60	Evidence for the O-sulfo derivative of MK-447 as active metabolite of MK-447. European Journal of Pharmacology, 1991, 200, 141-146.	1.7	5
61	Action of azelastine on intracellular Ca2+ in cultured airway smooth muscle. European Journal of Pharmacology, 1991, 205, 29-34.	1.7	14
62	Flow-dependent stimulation of sodium and cholesterol uptake and cell growth in cultured vascular smooth muscle. Journal of Hypertension, 1991, 9, 1029-1033.	0.3	17
63	The neurosteroid pregnenolone sulfate inhibits membrane anion transport and has natriuretic activity. Journal of Hypertension, 1991, 9, S290.	0.3	1
64	Evidence for a sulfo-conjugate as active metabolite of cicletanine. Journal of Hypertension, 1991, 9, S344.	0.3	1
65	Cadmium and membrane ion transport in a French urban male population. Bulletin of Environmental Contamination and Toxicology, 1991, 47, 850-857.	1.3	1
66	Kinetic study of the Ca2 + pump in erythrocytes from essential hypertensive patients. Journal of Hypertension, 1990, 8, 292.	0.3	17
67	Evidence for a DIOA-Sensitive [K+,C1~]-Cotransport System in Cultured Vascular Smooth Muscle Cells. American Journal of Hypertension, 1990, 3, 939-942.	1.0	13
68	Influence of environmental lead on membrane ion transport in a French urban male population. Environmental Research, 1990, 53, 105-118.	3.7	11
69	Inhibitory action of norepinephrine on sodium transport in vascular smooth muscle cells in culture. Pflugers Archiv European Journal of Physiology, 1989, 413, 493-497.	1.3	3
70	Evidence for a major route for zinc uptake in human red blood cells: [ZN(HCO3)2CL]?influx through the [Cl?/HCO3?] anion exchanger. Journal of Cellular Physiology, 1989, 138, 316-322.	2.0	60
71	Stimulation of the Na+, K+ Pump and the (Na+, K+, Cl-) Cotransport System by Endothelin-1 in Cultured Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 1989, 13, S213-215.	0.8	11
72	Demonstration of a Na+: Mg2+ exchange in human red cells by its sensitivity to tricyclic antidepressant drugs. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 338, 332-7.	1.4	57

#	Article	IF	Citations
73	High sensitivity of the Na⁺, K⁺â€pump of human red blood cells to genins of cardiac glycosides. British Journal of Pharmacology, 1988, 93, 803-810.	2.7	5
74	Blood pressure and erythrocyte Na+ transport systems in a French urban male population. Journal of Hypertension, 1988, 6, 905-911.	0.3	6
75	Disturbances in Na+ Transport Systems Induced by Ethanol in Human Red Blood Cells. Alcoholism: Clinical and Experimental Research, 1988, 12, 534-538.	1.4	5
76	Antihypertensive Effect of Canrenone in a Model Where Endogenous Ouabain-Like Factors are Present. Journal of Cardiovascular Pharmacology, 1988, 11, 75-83.	0.8	27
77	Inhibition of the Cl-/NaCO3- anion exchanger by xipamide in human red blood cells. European Journal of Pharmacology, 1987, 144, 353-362.	1.7	11
78	An Na+-stimulated Mg2+-transport system in human red blood cells. Biochimica Et Biophysica Acta - Biomembranes, 1986, 856, 76-84.	1.4	90
79	Na+Transport in Primary Hypertension. Annals of the New York Academy of Sciences, 1986, 488, 187-195.	1.8	11
80	Stimulation of beta-adrenoceptors inhibits calcium-dependent potassium-channels in mouse macrophages. Journal of Cellular Physiology, 1986, 129, 310-314.	2.0	22
81	Inhibition of the erythrocyte Na+, K+-pump by mammalian lignans. Pharmacological Research Communications, 1986, 18, 227-239.	0.2	20
82	Na+Transport in Primary Hypertension. Annals of the New York Academy of Sciences, 1986, 488, 187-195.	1.8	15
83	Na+ leak in erythrocytes from essential hypertensive patients. Clinical Science, 1985, 69, 613-624.	1.8	29
84	Interaction of BN 52021 and PAF-acether with membrane ion transport. Prostaglandins, 1985, 30, 712.	1.2	0
85	Involvement of cytosolic free calcium in the action mechanism of atrial natriuretic factor (ANF). Regulatory Peptides, 1985, 10, 101-103.	1.9	2
86	Correlation Between K+ Fluxes and the Arachidonic Acid Cascade in Human Leukocyte Stimulated with a 23187 or Melittin. , 1985, , 363-380.		0
87	Ion Transport Characteristics in Rhesus Monkey Erythrocytes: Relationship to Age and Blood Pressure. Clinical and Experimental Hypertension, 1984, 6, 961-978.	0.3	0
88	Stimulation of K+ fluxes by diuretic drugs in human red cells. Biochemical Pharmacology, 1984, 33, 2013-2020.	2.0	74
89	Interaction between K+-Transport, Membrane Potential and Prostacyclin Generation in the Regulation of Natriuresis. Contributions To Nephrology, 1984, 41, 23-26.	1.1	2
90	Erythrocyte Na+ and K+ transport systems in children with Bartter syndrome: Increase in passive sodium permeability. Kidney International, 1983, 23, 530-535.	2.6	10

#	Article	IF	Citations
91	IS A K + -PROSTACYCLIN INTERACTION INVOLVED IN THE MECHANISM OF ACTION OF SOME DIURETIC DRUGS?. Lancet, The, 1983, 321, 1218-1219.	6.3	4
92	Hypertension as a membrane disease. European Journal of Clinical Investigation, 1981, 11, 337-339.	1.7	15
93	Outward sodium and potassium cotransport in human red cells. Journal of Membrane Biology, 1981, 62, 169-174.	1.0	112
94	A Genetic Approach to the Geography of Hypertension : Examination of Na⁺-K⁺Cotransport in Ivory Coast Africans. Clinical and Experimental Hypertension, 1981, 3, 861-870.	1.2	36
95	Evidence for Imbalanced Furosemideâ€Sensitive Na⁺, K⁺ Cotransport in Hereditary Stomatocytosis. Scandinavian Journal of Haematology, 1981, 27, 365-373.	0.0	8
96	Erythrocyte Sodium Extrusion in Primary Hypertension. , 1981, , 81-83.		0
97	Inherited defect in a Na+, K+ -co-transport system in erythrocytes from essential hypertensive patients. Nature, 1980, 284, 281-283.	13.7	294
98	Laboratory Distinction between Essential and Secondary Hypertension by Measurement of Erythrocyte Cation Fluxes. New England Journal of Medicine, 1980, 302, 769-771.	13.9	177
99	A Na+,K+ co-transport assay for essential hypertension. Canadian Journal of Biochemistry, 1980, 58, 1069-1074.	1.4	68
100	Clinical and Pathogenic Relevance of Erythrocyte Cation Fluxes Measurement in Human Hypertension. , 1980, , 712-714.		0
101	POSITIVE HOMOTROPIC COOPERATIVITY OF PRESYNAPTIC [3H]-DIHYDRO-ERGOCRYPTINE BINDING IN RAT HEART MEMBRANES. , 1979, , 550-552.		0
102	A KINETIC STUDY OF THE Na PUMP IN RED CELLS: ITS RELEVANCE TO THE MECHANISM OF ACTIVE TRANSPORT. Annals of the New York Academy of Sciences, 1974, 242, 445-457.	1.8	34